|Description||GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for psoriasis, rheumatoid arthritis, and ulcerative colitis.|
|Brife Description||A potent and ATP competitive RIP1 inhibitor (IC50= 16 nM)|
|Related CAS||1987858-31-0 (hydrate)|
|Solubility||DMSO: ≥100 mg/mL|
|Storage||Store in a cool and dry place (or refer to the Certificate of Analysis).|
GSK2982772, with potential effect to treat inflammatory diseases, potently binds to RIP1 with exquisite kinase specificity. In phase 2a clinical studies for pso...
OD-36, a macrocycle compound, has been found to be a RIPK2 inhibitor that could decrease cellular infiltration induced by MDP in neutrophils and lymphocytes. IC...
GSK'872 is aRIPK3inhibitor, which binds RIP3 kinase domain with high affinity (IC50=1.8 nM), and is approximately >1,000-fold selective over 300 kinases in a fl...
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interacting protein 1 (RIP1) (IC50= 13 nM), and efficiently reduced tumor ...
WEHI-345, a pyrazolo-pyridine derivative, is a RIPK2 inhibitor and has been found to influence the production of inflammatory cytokine. IC50: 0.13 μM.